Neurology

Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market

Retrieved on: 
Saturday, February 17, 2024

Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN ) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in Times Square, New York, on February 15th, 2024.

Key Points: 
  • Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN ) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in Times Square, New York, on February 15th, 2024.
  • This major milestone underscored the company's commitment to its valued shareholders and its mission to develop commercially attractive, affordable, genetically unmodified off-the-shelf T cell therapies for large patient populations in virology, oncology, and neurology.
  • “This event not only reconfirmed company’s growth strategy but also reinforced our commitment to our mission.
  • As we embark on this new chapter, we look forward to contributing to the market's vibrancy and delivering value to our shareholders and patients.”

Quanterix Fourth Quarter Earnings and Full Year 2023 Financial Results Conference Call

Retrieved on: 
Friday, February 16, 2024

Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results.

Key Points: 
  • Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced it will host a conference call on Tuesday, February 27, 2024, to discuss its fourth quarter earnings and full year 2023 financial results.
  • It will be hosted by Masoud Toloue, the Company’s President and Chief Executive Officer, and Vandana Sriram, the Company’s Chief Financial Officer.
  • Quanterix will issue a press release regarding the fourth quarter 2023 earnings and full year 2023 financial results prior to the conference call.
  • You may also access the live webcast by visiting the News & Events page within the Investors section of the Quanterix website at www.quanterix.com .

Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights

Retrieved on: 
Friday, February 16, 2024

Spherix Global Insights’ Market Dynamix™: Parkinson’s Disease (US) study surveyed US neurologists (n=101) to analyze patient presentation patterns, current treatment paradigms, and need for potential DMTs.

Key Points: 
  • Spherix Global Insights’ Market Dynamix™: Parkinson’s Disease (US) study surveyed US neurologists (n=101) to analyze patient presentation patterns, current treatment paradigms, and need for potential DMTs.
  • Further, critical to the success of future gene therapies and DMTs is the identification of biomarkers associated with PD.
  • This underscores the importance of manufacturers engaging with healthcare professionals to provide insights into emerging therapies and MOAs.
  • Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 16, 2024

Real World Evidence Solutions Market Dynamics:

Key Points: 
  • Real World Evidence Solutions Market Dynamics:
    Key Market Players of Real World Evidence Solutions Industry:
    Prominent players in the Real-World Evidence Solution market include Iqvia Holdings Inc. (US), Merative(US), Optum Inc. (US), Icon Plc.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the Real-World Evidence Solution market.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Real-World Evidence Solution market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global real-world evidence solution Market.

Real World Evidence Solutions Market Worth $4.5 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 16, 2024

Real World Evidence Solutions Market Dynamics:

Key Points: 
  • Real World Evidence Solutions Market Dynamics:
    Key Market Players of Real World Evidence Solutions Industry:
    Prominent players in the Real-World Evidence Solution market include Iqvia Holdings Inc. (US), Merative(US), Optum Inc. (US), Icon Plc.
  • Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the Real-World Evidence Solution market.
  • Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the Real-World Evidence Solution market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global real-world evidence solution Market.

Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Retrieved on: 
Thursday, February 15, 2024

SAN DIEGO, Feb. 15, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will be presenting multiple posters from all three clinical development programs in rare muscle diseases, including new AOC 1001 long-term efficacy and safety data from the MARINA open-label extension (MARINA-OLE™) trial in people living with myotonic dystrophy type 1 (DM1) at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida.

Key Points: 
  • ET for a live video webcast event, which will be available on the company's website.
  • The company is hosting Volume 8 of its investor and analyst event series on March 4, 2024, beginning at 8:00 a.m.
  • ET to discuss new AOC 1001 long-term efficacy and safety data from the MARINA-OLE™ trial in people living with DM1.
  • A replay of the webcast will be archived on Avidity's website following the event.

Pyros Pharmaceuticals Announces Positive Outcome of the European Decentralised Procedure for Approval of VIGZIP™ (vigabatrin oral solution)

Retrieved on: 
Thursday, February 15, 2024

Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today the positive outcome of the Decentralised Procedure (DCP) for VIGZIP™ (vigabatrin oral solution) in Europe.

Key Points: 
  • Pyros Pharmaceuticals, Inc. (Pyros or the Company), a leader in the development of enhanced specialty pharmaceuticals for rare diseases, announced today the positive outcome of the Decentralised Procedure (DCP) for VIGZIP™ (vigabatrin oral solution) in Europe.
  • "We are incredibly pleased with the positive outcome supporting the approval of VIGZIP™ in several key European markets.
  • This achievement serves as a testament to our dedication to developing innovative solutions for unmet medical needs in rare pediatric diseases.
  • Pyros remains committed to expanding access to VIGZIP™ in other additional territories around the world,” stated Michael Smith, Chief Executive Officer of Pyros.

ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues

Retrieved on: 
Thursday, February 15, 2024

The lease, SPI may build a long-term care center for the elderly, plant factories, and good agricultural practices (GAP) for botanical drug products and dietary supplements.

Key Points: 
  • The lease, SPI may build a long-term care center for the elderly, plant factories, and good agricultural practices (GAP) for botanical drug products and dietary supplements.
  • ABVC agrees to grant SPI a license to use the Know-How for the healthcare industry.
  • Under the agreement, SPI shall pay ABVC $3M as the license fee for the Know-How, in cash or stock, and royalties of 2% on SPI's revenues earned from projects on the Land.
  • The Land can be repurposed for commercial or residential development, which we believe will allow ABVC to maximize its value.

Tevogen Bio Announces $8 Million Equity Investment

Retrieved on: 
Thursday, February 15, 2024

On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $8.0 million.

Key Points: 
  • On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $8.0 million.
  • “We are excited to begin our journey as a public company with this additional investment,” said Dr. Ryan Saadi, the Company’s Chief Executive Officer and Chairperson.
  • “We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare.
  • The Series A Preferred Stock is non-voting, has no mandatory redemption, carries an annual 5% cumulative dividend, increasing by 2% each year.

Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference

Retrieved on: 
Thursday, February 15, 2024

AMX0035 is marketed by Amylyx as RELYVRIO® and is approved to treat ALS in adults in the U.S. and approved with conditions as ALBRIOZA™ for the treatment of ALS in Canada.

Key Points: 
  • AMX0035 is marketed by Amylyx as RELYVRIO® and is approved to treat ALS in adults in the U.S. and approved with conditions as ALBRIOZA™ for the treatment of ALS in Canada.
  • This poster shares details on pre-clinical efficacy studies as well as introduces the design approach for the first-in-human study, anticipated to begin later this year.
  • The Company is studying multiple cellular pathways implicated in disease pathogenesis as we believe that it is going to take a combination approach to find a cure for ALS.
  • Additional information, including copies of the poster presentations, will be made available on the “ Publications ” tab of the Amylyx website, following the conclusion of the poster presentations.